Calpain activation and progression of inflammatory cycles in Parkinson’s disease

Parkinson’s disease (PD) is a progressive, neurodegenerative condition of the central nervous system (CNS) affecting 6.3 million people worldwide with no curative treatments. Current therapies aim to mitigate PD’s effects and offer symptomatic relief for patients. Multiple pathways are involved in t...

Full description

Bibliographic Details
Main Authors: Andrew Gao, Hannah M. McCoy, Vandana Zaman, Donald C. Shields, Naren L. Banik, Azizul Haque
Format: Article
Language:English
Published: IMR Press 2022-01-01
Series:Frontiers in Bioscience-Landmark
Subjects:
Online Access:https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701020
_version_ 1819025939140444160
author Andrew Gao
Hannah M. McCoy
Vandana Zaman
Donald C. Shields
Naren L. Banik
Azizul Haque
author_facet Andrew Gao
Hannah M. McCoy
Vandana Zaman
Donald C. Shields
Naren L. Banik
Azizul Haque
author_sort Andrew Gao
collection DOAJ
description Parkinson’s disease (PD) is a progressive, neurodegenerative condition of the central nervous system (CNS) affecting 6.3 million people worldwide with no curative treatments. Current therapies aim to mitigate PD’s effects and offer symptomatic relief for patients. Multiple pathways are involved in the pathogenesis of PD, leading to neuroinflammation and the destruction of dopaminergic neurons in the CNS. This review focuses on PD pathology and the role of calpain, a neutral protease, as a regulator of various immune cells such as T-cells, microglia and astrocytes which lead to persistent neuroinflammatory responses and neuronal loss in both the brain and spinal cord (SC). Calpain plays a significant role in the cleavage and aggregation of toxic α-synuclein (α-syn), a presynaptic neural protein, and other organelles, contributing to mitochondrial dysfunction and oxidative stress. α-Syn aggregation results in the formation of Lewy bodies (LB) that further contribute to neuronal damage through lipid bilayer penetration, calcium ion (Ca2+) influx, oxidative stress and damage to the blood brain barrier (BBB). Dysfunctional mitochondria destabilize cytosolic Ca2+ concentrations, raising intracellular Ca2+; this leads to excessive calpain activation and persistent inflammatory responses. α-Syn aggregation also results in the disruption of dopamine synthesis through phosphorylation of tyrosine hydroxylase (TH), a key enzyme involved in the conversion of tyrosine to levodopa (L-DOPA), the amino acid precursor to dopamine. Decreased dopamine levels result in altered dopamine receptor (DR) signaling, ultimately activating pro-inflammatory T-cells to further contribute to the inflammatory response. All of these processes, together, result in neuroinflammation, degeneration and ultimately neuronal death seen in PD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP—a prodrug to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+)), rotenone (an environmental neurotoxin), and 6-hydroxydopamine (6-OHDA - a neurotoxic synthetic organic compound) induce PD-like conditions when injected into rodents. All three agents work through similar mechanisms and lead to degeneration of dopaminergic neurons in the substantia nigra (SN) and more recently discovered in motor neurons of the spinal cord (SC). These neurotoxins also increase calpain activity, furthering the neuroinflammatory response. Hence, calpain inhibitors have been posited as potential therapeutics for PD to prevent calpain-related inflammation and neurodegenerative responses in not only the SN but the SC as well.
first_indexed 2024-12-21T05:18:39Z
format Article
id doaj.art-ddfa32cf1c074a9587f9e4d22c4b81d1
institution Directory Open Access Journal
issn 2768-6701
language English
last_indexed 2024-12-21T05:18:39Z
publishDate 2022-01-01
publisher IMR Press
record_format Article
series Frontiers in Bioscience-Landmark
spelling doaj.art-ddfa32cf1c074a9587f9e4d22c4b81d12022-12-21T19:14:52ZengIMR PressFrontiers in Bioscience-Landmark2768-67012022-01-0127102010.31083/j.fbl2701020S2768-6701(22)00358-6Calpain activation and progression of inflammatory cycles in Parkinson’s diseaseAndrew Gao0Hannah M. McCoy1Vandana Zaman2Donald C. Shields3Naren L. Banik4Azizul Haque5Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Neurosurgery, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Neurosurgery, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USADepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USAParkinson’s disease (PD) is a progressive, neurodegenerative condition of the central nervous system (CNS) affecting 6.3 million people worldwide with no curative treatments. Current therapies aim to mitigate PD’s effects and offer symptomatic relief for patients. Multiple pathways are involved in the pathogenesis of PD, leading to neuroinflammation and the destruction of dopaminergic neurons in the CNS. This review focuses on PD pathology and the role of calpain, a neutral protease, as a regulator of various immune cells such as T-cells, microglia and astrocytes which lead to persistent neuroinflammatory responses and neuronal loss in both the brain and spinal cord (SC). Calpain plays a significant role in the cleavage and aggregation of toxic α-synuclein (α-syn), a presynaptic neural protein, and other organelles, contributing to mitochondrial dysfunction and oxidative stress. α-Syn aggregation results in the formation of Lewy bodies (LB) that further contribute to neuronal damage through lipid bilayer penetration, calcium ion (Ca2+) influx, oxidative stress and damage to the blood brain barrier (BBB). Dysfunctional mitochondria destabilize cytosolic Ca2+ concentrations, raising intracellular Ca2+; this leads to excessive calpain activation and persistent inflammatory responses. α-Syn aggregation also results in the disruption of dopamine synthesis through phosphorylation of tyrosine hydroxylase (TH), a key enzyme involved in the conversion of tyrosine to levodopa (L-DOPA), the amino acid precursor to dopamine. Decreased dopamine levels result in altered dopamine receptor (DR) signaling, ultimately activating pro-inflammatory T-cells to further contribute to the inflammatory response. All of these processes, together, result in neuroinflammation, degeneration and ultimately neuronal death seen in PD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP—a prodrug to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+)), rotenone (an environmental neurotoxin), and 6-hydroxydopamine (6-OHDA - a neurotoxic synthetic organic compound) induce PD-like conditions when injected into rodents. All three agents work through similar mechanisms and lead to degeneration of dopaminergic neurons in the substantia nigra (SN) and more recently discovered in motor neurons of the spinal cord (SC). These neurotoxins also increase calpain activity, furthering the neuroinflammatory response. Hence, calpain inhibitors have been posited as potential therapeutics for PD to prevent calpain-related inflammation and neurodegenerative responses in not only the SN but the SC as well.https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701020α-synuclein (α-syn)calpaindopamineneurodegenerationneuroinflammationspinal cordparkinson's disease (pd)
spellingShingle Andrew Gao
Hannah M. McCoy
Vandana Zaman
Donald C. Shields
Naren L. Banik
Azizul Haque
Calpain activation and progression of inflammatory cycles in Parkinson’s disease
Frontiers in Bioscience-Landmark
α-synuclein (α-syn)
calpain
dopamine
neurodegeneration
neuroinflammation
spinal cord
parkinson's disease (pd)
title Calpain activation and progression of inflammatory cycles in Parkinson’s disease
title_full Calpain activation and progression of inflammatory cycles in Parkinson’s disease
title_fullStr Calpain activation and progression of inflammatory cycles in Parkinson’s disease
title_full_unstemmed Calpain activation and progression of inflammatory cycles in Parkinson’s disease
title_short Calpain activation and progression of inflammatory cycles in Parkinson’s disease
title_sort calpain activation and progression of inflammatory cycles in parkinson s disease
topic α-synuclein (α-syn)
calpain
dopamine
neurodegeneration
neuroinflammation
spinal cord
parkinson's disease (pd)
url https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701020
work_keys_str_mv AT andrewgao calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease
AT hannahmmccoy calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease
AT vandanazaman calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease
AT donaldcshields calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease
AT narenlbanik calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease
AT azizulhaque calpainactivationandprogressionofinflammatorycyclesinparkinsonsdisease